[Prognostic value of of the expression Ki-67, CD31, and VEGF in somatotropinomas]

Arkh Patol. 2010 Jan-Feb;72(1):35-8.
[Article in Russian]

Abstract

Pituitary adenomas are benign, but 30-50% of patients do not achieve remission after treatment. The purpose of the study was to analyze the prognostic value of immunoexpression of the proliferation marker Ki-67 and the angiogenetic factors CD31 and VEGF in somatotropinomas. Ki-67, CD31, and VEGF were immunohistochemically studied in the samples of 52 somatotropin-removed samples; medical records were used to analyze the outcome of treatment in the early and late postoperative periods. Ki-67 immunoexpression proved to be significantly higher in the patients who had not achieve remission both in the early (p = 0.042) and late (p = 0.012) postoperative period than in those who had achieved remission and in patients who were resistant to postoperative treatment with somatostatin analogues (p = 0.040) than in those who were sensitive to therapy. The immunoexpression of CD31 and VEGF was not associated with the outcome of treatment. Thus, high Ki-67 levels may be regarded as a poor postoperative prognostic factor in acromegaly.

MeSH terms

  • Adenoma / diagnosis
  • Adenoma / metabolism*
  • Adenoma / surgery
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen / biosynthesis*
  • Male
  • Middle Aged
  • Pituitary Neoplasms / diagnosis
  • Pituitary Neoplasms / metabolism*
  • Pituitary Neoplasms / surgery
  • Platelet Endothelial Cell Adhesion Molecule-1 / biosynthesis*
  • Prognosis
  • Vascular Endothelial Growth Factor A / biosynthesis*

Substances

  • Ki-67 Antigen
  • Platelet Endothelial Cell Adhesion Molecule-1
  • VEGFA protein, human
  • Vascular Endothelial Growth Factor A